Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Transplant Cell Ther. 2022 Apr 18;28(7):409.e1–409.e10. doi: 10.1016/j.jtct.2022.04.012

Table 2:

Three-Year Survival Probabilities with 95% CIs for Various Lymphomas, 2010–2019

Autologous HCT, % Allogeneic HCT, %
Chemosensitive Chemoresistant Chemosensitive Chemoresistant
MRD URD MRD URD
HL 90 (88–90) 78 (75–82) 71 (66–75) 64 (60–69) 47 (35–59) 58 (49–67)
FL 83 (81–85) 67 (58–76) 78 (74–83) 71 (66–75) 63 (50–76) 55 (44–66)
DLBCL 70 (69–71) 52 (48–56) 58 (54–62) 52 (48–56) 34 (27–42) 30 (23–37)

HL indicates Hodgkin lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B cell lymphoma